TY - JOUR
T1 - Current guidelines in defining therapeutic strategies
AU - Ferrajoli, Alessandra
AU - Keating, Michael J.
PY - 2004/8
Y1 - 2004/8
N2 - Current therapeutic strategies in CLL should offer the most active treatment available, nowadays a combination of chemoimmunotherapy; aiming at complete response; evaluating the presence of minimal residual disease; and the use of further strategies, such as monoclonal antibodies or immunotherapy with vaccines, to eradicate minimal residual disease. Risk stratification with special attention to genomic aberrations is necessary. Ongoing and future studies will allow us to validate prospectively the recently described prognostic factors.
AB - Current therapeutic strategies in CLL should offer the most active treatment available, nowadays a combination of chemoimmunotherapy; aiming at complete response; evaluating the presence of minimal residual disease; and the use of further strategies, such as monoclonal antibodies or immunotherapy with vaccines, to eradicate minimal residual disease. Risk stratification with special attention to genomic aberrations is necessary. Ongoing and future studies will allow us to validate prospectively the recently described prognostic factors.
UR - http://www.scopus.com/inward/record.url?scp=4344638367&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=4344638367&partnerID=8YFLogxK
U2 - 10.1016/j.hoc.2004.04.006
DO - 10.1016/j.hoc.2004.04.006
M3 - Review article
C2 - 15325704
AN - SCOPUS:4344638367
SN - 0889-8588
VL - 18
SP - 881
EP - 893
JO - Hematology/Oncology Clinics of North America
JF - Hematology/Oncology Clinics of North America
IS - 4
ER -